2024
Editorial for the themed issue: Addressing the dual challenges of opioid use disorder and chronic pain in the context of the opioid crisis
Sofuoglu M, MacLean R, De Aquino J. Editorial for the themed issue: Addressing the dual challenges of opioid use disorder and chronic pain in the context of the opioid crisis. British Journal Of Clinical Pharmacology 2024 PMID: 39340184, DOI: 10.1111/bcp.16273.Peer-Reviewed Original ResearchSex differences in comorbid pain and opioid use disorder: A scoping review
DeVito E, Ameral V, Sofuoglu M. Sex differences in comorbid pain and opioid use disorder: A scoping review. British Journal Of Clinical Pharmacology 2024 PMID: 39168150, DOI: 10.1111/bcp.16218.Peer-Reviewed Original ResearchOpioid use disorderChronic painTreatment of opioid use disorderChronic opioid usePost hoc analysisPersistent painClinical courseOpioid useComorbid painSex/gender differencesOpioid misuseOpioidPainUse disorderHighest prevalencePost-hocOutcome variablesDisordersTreatmentHuman subjectsBiological underpinningsPsychosocial factorsTreatment effectsSex differencesSexW82 Variation in Psychosocial Symptom Change: A Preliminary Examination of Veterans in Early Medication Treatment for Opioid Use Disorder
Wolkowicz N, Sofuoglu M, De Aquino J, MacLean R. W82 Variation in Psychosocial Symptom Change: A Preliminary Examination of Veterans in Early Medication Treatment for Opioid Use Disorder. Drug And Alcohol Dependence 2024, 260: 110700. DOI: 10.1016/j.drugalcdep.2023.110700.Peer-Reviewed Original ResearchW68 Greater Coupling of Pain Intensity and Opioid Craving After Delaying Methadone Dose Among Veterans With Opioid Use Disorder
MacLean R, Spinola S, Pittman B, Meyerovich J, Szollosy S, Wolkowicz N, Sofuoglu M. W68 Greater Coupling of Pain Intensity and Opioid Craving After Delaying Methadone Dose Among Veterans With Opioid Use Disorder. Drug And Alcohol Dependence 2024, 260: 110686. DOI: 10.1016/j.drugalcdep.2023.110686.Peer-Reviewed Original ResearchA preliminary investigation of the acute effects of delta-9-tetrahydrocannabinol on pain and opioid attentional bias among persons with opioid use disorder
Wolkowicz N, Sofuoglu M, Pittman B, Meyerovich J, MacLean R, De Aquino J. A preliminary investigation of the acute effects of delta-9-tetrahydrocannabinol on pain and opioid attentional bias among persons with opioid use disorder. Journal Of Psychiatric Research 2024, 177: 90-95. PMID: 38991269, PMCID: PMC11371499, DOI: 10.1016/j.jpsychires.2024.06.047.Peer-Reviewed Original ResearchAttentional biasOpioid use disorderDelta-9-tetrahydrocannabinolTHC administrationDose of methadoneOpioid cuesUse disorderEffects of delta-9-tetrahydrocannabinolLower doses of methadoneVisual probe taskHigher doses of methadoneEffects of cannabinoidsFive-hour sessionTHC doseOral THCProbe taskPsychoactive constituentAddictive propertiesMethadone patientsMethadone doseWithin-subjectTHCPreliminary evidenceMethadoneAcute effectsGlial modulators as novel therapeutics for comorbid pain and opioid use disorder
Schwartz E, De Aquino J, Sofuoglu M. Glial modulators as novel therapeutics for comorbid pain and opioid use disorder. British Journal Of Clinical Pharmacology 2024 PMID: 38752593, DOI: 10.1111/bcp.16094.Peer-Reviewed Original ResearchOpioid use disorderChronic painGlial modulationNovel treatment approachesComorbid painPublic health problemTreatment approachesImproved pain measuresLiterature search of PubMedIncreased opioid prescriptionsSearch of PubMedAddiction-related outcomesSignificant public health problemComorbid disordersOpioid prescriptionsGoogle Scholar databasesPain measuresHealth problemsPain managementClinical studiesTreatment challengesClinical trialsPatient populationPainGlial activationFrom taboo to treatment: The emergence of psychedelics in the management of pain and opioid use disorder
Weleff J, Nunes J, Costa G, Sofuoglu M, MacLean R, De Aquino J. From taboo to treatment: The emergence of psychedelics in the management of pain and opioid use disorder. British Journal Of Clinical Pharmacology 2024 PMID: 38627909, PMCID: PMC11480258, DOI: 10.1111/bcp.16045.Peer-Reviewed Original ResearchOpioid use disorderChronic painLong-term opioid therapyManagement of chronic painPain management alternativeOpioid-induced analgesiaInnovative treatment optionsManagement of painReverse painCentral sensitizationOpioid therapyPain controlTreatment optionsClinical challengeClinical trialsPainPotential therapeutic applicationsPain experiencePotential of psychedelicsNovel therapeuticsHuman evidenceOpioid crisisNeurobiological substratesOpioidExploration of novel therapeuticsThe relationship of pain intensity and opioid craving with delayed methadone dose: A preliminary study of individuals with opioid use disorder
MacLean R, Spinola S, Pittman B, Meyerovich J, Szollosy S, Wolkowicz N, Minnix S, Sofuoglu M. The relationship of pain intensity and opioid craving with delayed methadone dose: A preliminary study of individuals with opioid use disorder. British Journal Of Clinical Pharmacology 2024 PMID: 38439592, DOI: 10.1111/bcp.16027.Peer-Reviewed Original ResearchCold pressor testMethadone doseExperience of painOpioid cravingMethadone conditionTime course of painRelationship of pain intensityDose conditionsCourse of painAssessment of painOpioid use disorderCross-over designPain intensityPain thresholdIncreased riskPainStudy visitsPressor testDelayed dosesUse disorderCravingOpioidMethadone treatmentDoseMethadone
2023
Brief report: The influence of childhood trauma on the effects of delta‐9‐tetrahydrocannabinol in persons with opioid use disorder
Rogan M, Nunes J, Xie C, Sofuoglu M, Pittman B, De Aquino J. Brief report: The influence of childhood trauma on the effects of delta‐9‐tetrahydrocannabinol in persons with opioid use disorder. American Journal On Addictions 2023, 33: 343-346. PMID: 38059660, PMCID: PMC11032222, DOI: 10.1111/ajad.13504.Peer-Reviewed Original ResearchDelta‐9‐tetrahydrocannabinol modulates pain sensitivity among persons receiving opioid agonist therapy for opioid use disorder: A within‐subject, randomized, placebo‐controlled laboratory study
De Aquino J, Meyerovich J, Xie C, Ranganathan M, Compton P, Pittman B, Rogan M, Sofuoglu M. Delta‐9‐tetrahydrocannabinol modulates pain sensitivity among persons receiving opioid agonist therapy for opioid use disorder: A within‐subject, randomized, placebo‐controlled laboratory study. Addiction Biology 2023, 28: e13317. PMID: 37644897, PMCID: PMC10468603, DOI: 10.1111/adb.13317.Peer-Reviewed Original ResearchConceptsOpioid use disorderOpioid agonist therapyAgonist therapyMethadone dosesMethadone therapyPain sensitivityUse disordersPlacebo-controlled laboratory studySynergistic antinociceptive effectCognitive adverse effectsSingle oral dosesRisk-benefit profilePain sensitivity measuresCannabinoid receptor systemAntinociceptive effectTHC doseOral dosesOpioid agonistsAcute effectsCannabinoid agonistsPreclinical studiesAbuse potentialOpioid crisisTherapyReceptor systemDeveloping non-opioid therapeutics to alleviate pain among persons with opioid use disorder: a review of the human evidence
Oliveira D, Fontenele R, Weleff J, Sofuoglu M, De Aquino J. Developing non-opioid therapeutics to alleviate pain among persons with opioid use disorder: a review of the human evidence. International Review Of Psychiatry 2023, 35: 377-396. PMID: 38299655, PMCID: PMC10835074, DOI: 10.1080/09540261.2023.2229430.Peer-Reviewed Original ResearchOpioid agonist therapyOpioid use disorderNon-opioid analgesicsUse disordersNon-opioid analgesic therapyAlpha-2 adrenergic agonistsMajor public health concernGlial activation inhibitorNon-opioid therapeuticsNovel analgesic strategiesPotential of cannabinoidsPrior opioid exposureOpioid-dependent individualsOpioid-dependent populationsAbuse liability assessmentPublic health concernAnalgesic strategiesAgonist therapyAnalgesic therapyOpioid exposureOUD treatmentPharmacokinetic interactionsGABAergic drugsSignificant morbidityPain typesIntegrating cognitive bias modification for pain and opioid cues into medication for opioid use disorder clinical care: Feasibility, acceptability, and preliminary results
MacLean R, Heapy A, Waters A, Wolkowicz N, Szollosy S, Meyerovich J, Sofuoglu M. Integrating cognitive bias modification for pain and opioid cues into medication for opioid use disorder clinical care: Feasibility, acceptability, and preliminary results. Drug And Alcohol Dependence 2023, 246: 109857. PMID: 37004461, PMCID: PMC10189744, DOI: 10.1016/j.drugalcdep.2023.109857.Peer-Reviewed Original ResearchConceptsTrial-level bias scoresOpioid cuesAB taskCognitive bias modification taskAttentional bias taskCognitive bias modificationComputer-based tasksPreliminary efficacyOpioid use disorderCurrent studyBias modificationBias taskBias scoresModification tasksCBM groupCBM tasksChronic painAcceptability measuresControl conditionTaskUse disordersClinical careCuesTime interactionParticipantsOpioid Use Disorder With Chronic Pain Increases Disease Burden and Service Use
MacLean RR, Sofuoglu M, Stefanovics E, Rosenheck R. Opioid Use Disorder With Chronic Pain Increases Disease Burden and Service Use. Psychological Services 2023, 20: 157-165. PMID: 34968125, PMCID: PMC9358616, DOI: 10.1037/ser0000607.Peer-Reviewed Original ResearchConceptsOpioid use disorderChronic painMental health diagnosesService useUse disordersHealth AdministrationConcurrent opioid use disorderHealth diagnosisOngoing opioid epidemicOutpatient service useVeterans Health AdministrationMental health disordersSubstance use diagnosesSingle disorder groupsClinical service useOpioid prescriptionsAdditional comorbiditiesMultinomial regression analysisDisease burdenMedication fillsOpioid epidemicPrescription opiatesMedical conditionsMedical disordersUse diagnoses
2022
Alleviation of opioid withdrawal by cannabis and delta-9-tetrahydrocannabinol: A systematic review of observational and experimental human studies
De Aquino J, Bahji A, Gómez O, Sofuoglu M. Alleviation of opioid withdrawal by cannabis and delta-9-tetrahydrocannabinol: A systematic review of observational and experimental human studies. Drug And Alcohol Dependence 2022, 241: 109702. PMID: 36434879, PMCID: PMC9772106, DOI: 10.1016/j.drugalcdep.2022.109702.Peer-Reviewed Original ResearchConceptsOpioid withdrawalObservational studySystematic reviewDelta-9-tetrahydrocannabinol administrationPlacebo-controlled clinical trialCannabis useNon-opioid therapeuticsPotential of cannabinoidsDose of opioidsOpioid withdrawal symptomsOpioid use disorderNarrow therapeutic windowExperimental human studiesDose-dependent increaseMain psychoactive constituentPatient characteristicsWithdrawal symptomsClinical trialsPharmacological factorsStudy qualityTherapeutic windowTherapeutic benefitUse disordersHuman studiesAbuse liability
2021
Opioid-induced analgesia among persons with opioid use disorder receiving methadone or buprenorphine: A systematic review of experimental pain studies
De Aquino JP, Parida S, Avila-Quintero VJ, Flores J, Compton P, Hickey T, Gómez O, Sofuoglu M. Opioid-induced analgesia among persons with opioid use disorder receiving methadone or buprenorphine: A systematic review of experimental pain studies. Drug And Alcohol Dependence 2021, 228: 109097. PMID: 34601272, PMCID: PMC8595687, DOI: 10.1016/j.drugalcdep.2021.109097.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyOpioid use disorderExperimental pain studiesAbuse potentialRespiratory depressionAcute painPain studiesUse disordersSystematic reviewGreater abuse potentialHigh-potency opioidsMethadone-maintained personsSignificant pain reliefRespiratory depressant effectsHigh-potency compoundsOpioid naïveAgonist therapyOpioid dosesPain reliefAnalgesic effectSevere painDepressant effectAdditional dosesStudy qualityHealthy personsThe Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder
De Aquino JP, Parida S, Sofuoglu M. The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder. Clinical Drug Investigation 2021, 41: 425-436. PMID: 33818748, PMCID: PMC8020374, DOI: 10.1007/s40261-021-01032-7.Peer-Reviewed Original ResearchConceptsUnique pharmacological profileOpioid use disorderOpioid withdrawalPotential dose-dependent effectsPlacebo-controlled clinical trialLong-term treatment outcomesFull opioid agonistsStandard induction regimensOpen-label studyFirst-line pharmacotherapySchedule of administrationMu-opioid receptorsAvailability of buprenorphineDose-dependent effectFuture translational researchInduction regimensOpioid taperOpioid toneFirst doseClinical outcomesClinical evidenceOpioid agonistsBuprenorphine formulationsDaily dosesClinical trialsThe Impact of Chronic Pain on Opioid Use Disorder Treatment Outcomes
MacLean R, Spinola S, Garcia-Vassallo G, Sofuoglu M. The Impact of Chronic Pain on Opioid Use Disorder Treatment Outcomes. Current Addiction Reports 2021, 8: 100-108. DOI: 10.1007/s40429-020-00352-6.Peer-Reviewed Original ResearchOpioid agonist treatmentChronic painOpioid use disorderOpioid Use Disorder Treatment OutcomesNonpharmacologic pain treatmentsIllicit opioid useDisorder treatment outcomesReviewChronic painOpioid usePain intensityPain treatmentAgonist treatmentOAT clinicsTreatment outcomesClinical carePainUse disordersDrug useRecent FindingsWeHigher likelihoodClinicOutcomesTreatmentMost studiesIntake
2019
Pharmacotherapies for PTSD and Substance Use Disorders
Kachadourian L, Jensen K, Sofuoglu M, Petrakis I. Pharmacotherapies for PTSD and Substance Use Disorders. 2019, 239-259. DOI: 10.4324/9781315442648-13.ChaptersOpioid use disorderAlcohol use disorderPosttraumatic stress disorderUse disordersPTSD/SUDPharmacological treatmentComorbid posttraumatic stress disorderUse of pharmacotherapySubstance use disordersEffectiveness of foodIntramuscular naltrexoneLabel medicationsEpidemiological studiesMedication developmentDrug AdministrationPharmacotherapyStress disorderAvailable evidenceDisordersNew targetsNaltrexoneTreatmentBiological mechanismsSpecific substancesSUD
2018
Minocycline does not affect experimental pain or addiction-related outcomes in opioid maintained patients
Arout CA, Waters AJ, MacLean RR, Compton P, Sofuoglu M. Minocycline does not affect experimental pain or addiction-related outcomes in opioid maintained patients. Psychopharmacology 2018, 236: 2857-2866. PMID: 30564869, PMCID: PMC6581631, DOI: 10.1007/s00213-018-5146-7.Peer-Reviewed Original ResearchConceptsOpioid-induced hyperalgesiaCold pressor testOpioid use disorderSerum cytokinesPain thresholdUse disordersAddiction-related outcomesProinflammatory serum cytokinesActivation of microgliaSeverity of painEcological momentary assessmentEnd of treatmentHuman laboratory studiesTest sessionsOpioid cravingMinocycline treatmentOpioid toleranceAgonist treatmentPain sensitivityVisit 1Minocycline effectsPressor testExperimental painPreclinical studiesGo/No-Go taskPharmacological and Behavioral Treatment of Opioid Use Disorder
Sofuoglu M, DeVito E, Carroll K. Pharmacological and Behavioral Treatment of Opioid Use Disorder. Psychiatric Research And Clinical Practice 2018, 1: 4-15. PMCID: PMC9175946, DOI: 10.1176/appi.prcp.20180006.Peer-Reviewed Original ResearchOpioid use disorderMedication-assisted treatmentSubstance use conditionsBehavioral treatmentTreatment retentionUse disordersBehavioral interventionsOpioid withdrawal symptomsFirst-line treatmentMechanism of actionOUD treatmentComorbid conditionsMedication complianceWithdrawal symptomsClinical overviewClinical guidelinesOpioid receptorsAdrenergic agonistsNonsystematic reviewDrug AdministrationKey pharmacologicalBehavioral therapyTreatment effectivenessComplex needsTreatment